The FDA restricted many peptides in 2023, and HHS signaled a partial reversal in early 2026, but nothing is fully settled
The GLP-1 receptor agonist component is considered, based on established class effects, a likely contributor to these gastrointestinal adverse events, as GLP-1 activation slows gastric emptying and alters intestinal transit time
Retatrutide is an investigational once-weekly subcutaneous peptide that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, increase energy expenditure, and promote fat breakdown, though it has not yet received MHRA or EMA authorisation
Read This Before You Lose More Weight GLP-1 medications can be incredibly effective for weight lossbut protecting your metabolism is just as important as losing pounds
There is no single cause for the ever-increasing price of prescription drugs in the United States, although a fragmented reimbursement system, intermediaries like pharmacy benefit managers (PBMs), and a lack of price transparency, all bear a portion of the responsibility